secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001682852-23-000004
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna reports prelim 2022 COVID sales $18.4B; reiterates 2023 $5B min; RSV study accrues cases
--------------------------------------------------------------------------------

- Prelim 2022 COVID vaccine sales ~$18.4B; R&D ~$3.3B; cash & investments >$18B.
- 2023 min COVID sales reiterated at ~$5B; R&D budget rises to ~$4.5B.
- RSV vaccine (mRNA-1345) Phase 3 in older adults accrued enough cases for first interim efficacy analysis.
- Personalized cancer vaccine mRNA-4157 + Keytruda reduced recurrence risk by 44% in melanoma; Phase 3 to start 2023.
- Repurchased 23M shares for $3.3B in 2022; $2.8B remaining; acquired OriCiro Genomics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000004/0001682852-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000004/mrna-20230109.htm
  HTML page:      https://secwatch.observer/filing/0001682852-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer